Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Inclusion Criteria: * female sex; * age 40-65 years; * FVLS 2-4; * asking for midface volume restoration; * available and able to return to the study site for the post-procedural follow-up examinations; * agreeing to present at each study visit without make-up; * accepting to not change their habits regarding food, physical activity, make-up use, face cosmetic and cleansing products; * accepting not to expose their face to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection; * accepting to sign the informed consent form. Exclusion Criteria: * Pregnancy; * lactation; * smokers; * alcohol or drug abusers; * subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study; * subjects not in menopause who do not accept to perform the pregnancy test at T0 (before the first aesthetic procedure) and at T1 (3-4 weeks after the first injection treatment execution, before the touch-up aestetic procedure); * Body Mass Index (BMI) variation (± 1) during the study period; * performing skin treatments for aesthetic correction (biomaterials implants, face lifting, botox injections, laser, chemical peeling) in the 6 months prior to the study start; * performing permanent filler in the past; * change in the normal habits regarding food, physical activity, face cosmetic, cleansing and make-up use during the month preceding the test; * sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit); * subjects whose insufficient adhesion to the study protocol is foreseeable; * participation in a similar study currently or during the previous 3 months. * dermatitis; presence of cutaneous disease on the tested area, as lesions, scars, malformations; * recurrent facial/labial herpes; * clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, severe rosacea, scleroderma, local infections and severe acne). * diabetes; * endocrine disease; * hepatic disorder; * renal disorder; * cardiac disorder; * pulmonary disease; * cancer; * neurological or psychological disease; * inflammatory/immunosuppressive disease; * drug allergy. * anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago); * using of drugs able to influence the test results in the investigator opinion.